Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Clear cell renal cell carcinoma (ccRCC) is one of the most prevalent malignant diseases in the urinary system with more than 140,000 related deaths annually. Ubiquitination–deubiquitination homeostasis is an important factor in ccRCC progression; ubiquitin‐specific peptidase 53 (USP53) belongs to the family of deubiquitinating enzymes, but its functions are rarely reported.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Databases obtained from GEO and TCGA were analyzed to reveal the role of USP53 in ccRCC. CCK‐8/BrdU and EDU assays were used to detect the proliferation of ccRCC after USP53 overexpression or knockdown. A tumor xenograft experiment was used to verify the effect of the proliferation of ccRCC after USP53 knockdown. Transwell assays were used to detect the metastasis of ccRCC after USP53 overexpression or knockdown. RNA sequencing and western blot analysis were employed to detect the change in genes after USP53 overexpression and knockdown. Then we tested the effect of USP53 on IκBα protein stability through western blot analysis. Detect the effect of USP53 on IκBα ubiquitination in vitro by immunoprecipitation method.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>USP53 expression was downregulated in ccRCC tissues and USP53 expression was significantly negatively correlated with the tumor progression and clinical prognosis. The ability of growth and metastasis of ccRCC was inhibited after USP53 overexpression. In addition, USP53 knockdown promoted ccRCC growth and metastasis. Moreover, USP53 knockdown promoted the ability of clone formation of ccRCC <i>in vivo</i>. NF‐κB signaling pathway significantly enriched and downregulated in USP53 overexpressed cells, and genes in the NF‐κB pathway (such as IL1B, CXCL1‐3, RELA, RELB, etc.) were obviously downregulated in USP53 overexpressed cells. USP53 overexpression decreased the phosphorylation of IKKβ and P65 in both Caki‐1 and 786‐O cells, and the expression of IκBα was increased. Phosphorylation of IKKβ and P65 was increased in both Caki‐1 and 786‐O cells after USP53 knockdown. As the expression of USP53 increases, the protein expression of IκBα was also gradually increased and USP53 reduced the ubiquitination of IκBα. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>In summary, our data indicate that USP53 inhibits the inactivation of the NF‐κB pathway by reducing the ubiquitination of IκBα to further inhibit ccRCC proliferation and metastasis. These findings may help understand the pathogenesis of ccRCC and introduce new potential therapeutic targets for kidney cancer patients.</p></section>

USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer

The role of deubiquitinase USP2 in driving bladder cancer progression by stabilizing EZH2 to epigenetically silence SOX1 expression

USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response

Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma

USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma

USP39 promotes tumorigenesis by stabilizing and deubiquitinating SP1 protein in hepatocellular carcinoma

Deubiquitination of the Repressor E2F6 by USP22 Facilitates AKT Activation and Tumor Growth in Hepatocellular Carcinoma

USP7 depletion potentiates HIF2α degradation and inhibits clear cell renal cell carcinoma progression

The Deubiquitinase USP21 Stabilizes MEK2 to Promote Tumor Growth

USP9X destabilizes pVHL and promotes cell proliferation.

USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein

USP22 Upregulates ZEB1-mediated VEGFA Transcription in Hepatocellular Carcinoma

Downregulation of Ubiquitin-Specific Protease 2 Possesses Prognostic and Diagnostic Value and Promotes the Clear Cell Renal Cell Carcinoma Progression

Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1

Ubiquitin‐specific peptidase 53 inhibits the occurrence and development of clear cell renal cell carcinoma through NF‐κB pathway inactivation

Knockdown of Ubiquitin‐specific Peptidase 13 Inhibits Cell Growth of Hepatocellular Carcinoma by Reducing C‐myc Expression

Usp51 Promotes Deubiquitination and Stabilization of Zeb1

Dysregulation and oncogenic activities of ubiquitin specific peptidase 2a in the pathogenesis of hepatocellular carcinoma

Ubiquitin-specific protease 21 promotes tumorigenicity and stemness of colorectal cancer by deubiquitinating and stabilizing ZEB1

USP18 promotes tumor metastasis in esophageal squamous cell carcinomas via deubiquitinating ZEB1

VHL Substrate Transcription Factor ZHX2 As an Oncogenic Driver in Clear Cell Renal Cell Carcinoma